References 1. Lippincott-Schwartz J, Roberts TH, Hirschberg K (2000) Secretory protein trafficking and organelle dynamics in living cells. Annu Rev Cell Dev Biol 16: 557–589. 2. Sells SF, Wood DP, Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, et al. (1994) Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5: 457–466. 3. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, et al. (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138: 377–388. 4. Chen PS, Shih YW, Huang HC, Cheng HW (2011) Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One 6: e20164. 5. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, et al. (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer 86: 204–207. 6. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, et al. (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10: 7621–7628. 7. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, et al. (2002) Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17–25. 8. Brand K, Baker AH, Perez-Canto A, Possling A, Sacharjat M, et al. (2000) Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60: 5723–5730. 9. Zucker S, Cao J (2009) Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther 8: 2371–2373. 10. Koppikar SJ, Choudhari AS, Suryavanshi SA, Kumari S, Chattopadhyay S, et al. (2010) Aqueous cinnamon extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential. BMC Cancer 10: 210. 11. Zhen MC, Huang XH, Wang Q, Sun K, Liu YJ, et al. (2006) Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol Sin 27: 1600–1607. 12. Banerji A, Chakrabarti J, Mitra A, Chatterjee A (2004) Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett 211: 235– 242. 13. Kim MM, Kim SK (2006) Chitooligosaccharides inhibit activation and expression of matrix metalloproteinase-2 in human dermal fibroblasts. FEBS Lett 580: 2661–2666. 14. Weissenberg M, Lavie D, Glotter E (1977) 1-Oxo-steroids. Part 2. Model studies for the synthesis of the withanolides. J Chem Soc Perkin 1: 795–801. 15. Sudhir S, Budhiraja RD, Miglani GP, Arora B, Gupta LC, et al. (1986) Pharmacological studies on leaves of Withania somnifera. Planta Med: 61–63. 16. Falsey RR, Marron MT, Gunaherath GM, Shirahatti N, Mahadevan D, et al. (2006) Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat Chem Biol 2: 33–38. 17. Bargagna-Mohan P, Hamza A, Kim YE, Khuan Abby Ho Y, Mor-Vaknin N, et al. (2007) The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 14: 623–634. 18. Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, et al. (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 7: 115– 122. 19. Jayaprakasam B, Zhang Y, Seeram NP, Nair MG (2003) Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci 74: 125–132. 20. Shohat B, Gitter S, Abraham A, Lavie D (1967) Antitumor activity of withaferin A (NSC-101088). Cancer Chemother Rep 51: 271–276. 21. Yang H, Shi G, Dou QP (2007) The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry". Mol Pharmacol 71: 426–437. 22. Sen N, Banerjee B, Das BB, Ganguly A, Sen T, et al. (2007) Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ 14: 358–367. 23. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, et al. (2008) Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis 13: 1494–1504. 24. Anbalagan K, Sadique J (1984) Role of prostaglandins in acute phase proteins in inflammation. Biochem Med 31: 236–245. 25. Yousuf SK, Majeed R, Ahmad M, Sangwan P, Purnima B, et al. (2011) Ring A structural modified derivatives of withaferin A and the evaluation of their cytotoxic potential. Steroids 76: 1213–1222. 3-azidoWA Blocks MMP-2 and Induces Secretory Par-4 26. Prakash J, Gupta SK, Dinda AK (2002) Withania somnifera root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. Nutr Cancer 42: 91–97. 27. Ichikawa H, Takada Y, Shishodia S, Jayaprakasam B, Nair MG, et al. (2006) Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogen- esis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther 5: 1434–1445. 28. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52–67. 29. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, et al. (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9: 893–904. 30. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, et al. (2005) Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33–44. 31. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM (2001) Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61: 7255–7263. 32. Chetty C, Bhoopathi P, Lakka SS, Rao JS (2007) MMP-2 siRNA induced Fas/ CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarci- noma cell line. Oncogene 26: 7675–7683. 33. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 1424–1432. 34. Reddy KB, Nabha SM, Atanaskova N (2003) Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395–403. 35. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–257. 36. Cuniasse P, Devel L, Makaritis A, Beau F, Georgiadis D, et al. (2005) Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs. Biochimie 87: 393–402. 37. Kour K, Pandey A, Suri KA, Satti NK, Gupta KK, et al. (2009) Restoration of stress-induced altered T cell function and corresponding cytokines patterns by Withanolide A. Int Immunopharmacol 9: 1137–1144. 38. Malik F, Kumar A, Bhushan S, Khan S, Bhatia A, et al. (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis 12: 2115–2133. 39. Srinivasan S, Ranga RS, Burikhanov R, Han SS, Chendil D (2007) Par-4- dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res 67: 246–253. 40. Stearns M, Stearns ME (1996) Evidence for increased activated metalloprotei- nase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8: 69–75. 41. Duffy MJ, McGowan PM, Gallagher WM (2008) Cancer invasion and metastasis: changing views. J Pathol 214: 283–293. 42. Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, et al. (2009) Upregulation of MMP-2 by HMGA1 promotes transformation in undifferen- tiated, large-cell lung cancer. Mol Cancer Res 7: 1803–1812. 43. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174. 44. Overall CM, Kleifeld O (2006) Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227–239. 45. Mitsiades N, Poulaki V, Mitsiades CS, Anderson KC (2001) Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Investig Drugs 10: 1075–1084. 46. Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, et al. (2004) Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23: 3732–3736. 47. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, et al. (2006) Adenovirus- mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5: 2289–2299. 48. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118: 1979–1990. 49. Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, et al. (2006) Prostate- apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk Res 30: 597–605. 50. Kim D, Kim S, Koh H, Yoon SO, Chung AS, et al. (2001) Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15: 1953–1962. 51. Samuels Y, Ericson K (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77–82. PLOS ONE | www.plosone.org 14 September 2012 | Volume 7 | Issue 9 | e44039